Molecular Targets and Immunotherapy for Autoimmune Diseases
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: 30 August 2024 | Viewed by 185
Special Issue Editor
Special Issue Information
Dear Colleagues,
Autoimmune diseases are chronic pathological conditions resulting from a dysregulated immune response that fails to recognize self-antigens. Genetic predisposition and environmental factors contribute to the initiation of autoimmunity, ultimately leading to long-term tissue destruction. Conventional treatments of autoimmune diseases often rely on suppressing the general immune functions to control inflammation. However, these approaches are not entirely successful as non-selective immune suppression leads to inadvertent side effects, particularly the risk of developing infection. Recent advancements in genetic engineering tools resulted in the development of more targeted immunotherapies, such as cytokine-based (anti-TNFa, IL1b, IL6, and IL-17), cell-targeted therapies (anti-CD20 mAb, CTLA4-IgG1, etc.), and small-molecule inhibitors (JAK1/2/3, Tyk2, and BTK). Currently, antigen-specific immunotherapies utilizing more specific CAR T cells are beginning to emerge; however, their efficacy and long-term safety in a heterogenous population remains to be determined.
In this Special Issue, we aim to provide a comprehensive overview of the pathophysiological mechanisms of autoimmune diseases. We welcome manuscripts that address the deeper signaling pathways with the purpose of identifying novel molecular targets in autoimmune diseases. In this Special Issue, we give special emphasis to emerging targeted immunotherapies that can provide effective, safe, and long-term immune tolerance. We encourage the submission of review articles as well as original research papers.
Dr. Neetu Srivastava
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- autoimmunity
- autoimmune diseases
- immunotherapy
- signaling pathway
- molecular targets
- antibody
- T cells
- B cells
